| 5.965 -0.235 (-3.79%) | 01-26 14:53 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.73 | 1-year : | 9.03 |
| Resists | First : | 6.61 | Second : | 7.73 |
| Pivot price | 5.93  |
|||
| Supports | First : | 5.75 | Second : | 5.21 |
| MAs | MA(5) : | 6.14 |
MA(20) : | 5.88 |
| MA(100) : | 5.4 |
MA(250) : | 5.97 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 68 |
D(3) : | 72.2 |
| RSI | RSI(14): 53 |
|||
| 52-week | High : | 13.68 | Low : | 4.25 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CADL ] has closed below upper band by 43.6%. Bollinger Bands are 4.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.3 - 6.34 | 6.34 - 6.36 |
| Low: | 6.07 - 6.12 | 6.12 - 6.16 |
| Close: | 6.14 - 6.21 | 6.21 - 6.26 |
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.
Wed, 21 Jan 2026
Candel Therapeutics (NASDAQ:CADL) Stock Rating Lowered by Zacks Research - MarketBeat
Sat, 17 Jan 2026
Breakeven On The Horizon For Candel Therapeutics, Inc. (NASDAQ:CADL) - Sahm
Sat, 17 Jan 2026
Breakeven On The Horizon For Candel Therapeutics, Inc. (NASDAQ:CADL) - simplywall.st
Wed, 14 Jan 2026
Loss-Making Candel Therapeutics, Inc. (NASDAQ:CADL) Expected To Breakeven In The Medium-Term - Yahoo Finance
Fri, 12 Dec 2025
Is Candel Therapeutics On The Move With Pipeline Progress And Market Momentum? - RTTNews
Thu, 04 Dec 2025
Candel Therapeutics, Inc. (CADL) Stock Analysis: Unveiling a 271% Potential Upside in Biotech - DirectorsTalk Interviews
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 55 (M) |
| Shares Float | 45 (M) |
| Held by Insiders | 16.7 (%) |
| Held by Institutions | 41.8 (%) |
| Shares Short | 9,190 (K) |
| Shares Short P.Month | 8,270 (K) |
| EPS | -0.57 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.46 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -43.3 % |
| Return on Equity (ttm) | -70.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.43 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.71 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -34 (M) |
| Levered Free Cash Flow | -21 (M) |
| PE Ratio | -10.75 |
| PEG Ratio | 0 |
| Price to Book value | 4.12 |
| Price to Sales | 0 |
| Price to Cash Flow | -9.85 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|